Mangoceuticals, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | $456.0K | $615.9K | $731.5K | $8.9K |
| Cost of Revenue | — | $54.4K | $93.3K | $154.9K | $4.1K |
| Gross Profit | — | $250.4K | $380.0K | $431.5K | $4.9K |
| Gross Margin | — | 54.9% | 61.7% | 59.0% | 54.3% |
| Operating Expenses | |||||
| Research & Development | — | — | — | — | — |
| SG&A Expense | — | $3.8M | $3.0M | $3.3M | $1.6M |
| Operating Income | — | $-18.0M | $-8.0M | $-9.2M | $-2.0M |
| Operating Margin | — | -3,954.3% | -1,294.4% | -1,260.3% | -22,279.7% |
| Interest Expense | — | — | — | $-6.5K | $6.5K |
| Pretax Income | — | $-20.6M | $-8.7M | $-9.2M | $-2.0M |
| Income Tax Expense | — | — | — | — | — |
| Net Income | — | $-20.6M | $-8.7M | $-9.2M | $-2.0M |
| Net Margin | — | -4,526.8% | -1,413.6% | -1,259.4% | -22,352.1% |
| EPS (Basic) | — | $-2.17 | $-0.96 | $-1.72 | $-0.04 |
| EPS (Diluted) | — | $-2.17 | $-0.96 | $-1.72 | $-0.04 |
| Shares Outstanding (Basic) | 17.0M | 10.1M | 9.9M | 5.4M | 54.0M |
| Shares Outstanding (Diluted) | 17.0M | 10.1M | 9.9M | 5.4M | 54.0M |
| Dividends Per Share | — | — | — | — | — |